M P H van den Broek1, J E Möhlmann2, B G S Abeln3, M Liebregts3, V F van Dijk3, E M W van de Garde2,4. 1. Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. mp.van.den.broek@antoniusziekenhuis.nl. 2. Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. 3. Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. 4. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Abstract
BACKGROUND: In the battle against the SARS-CoV‑2 pandemic, chloroquine has emerged as a new potential therapeutic option for the treatment of infected patients. A safety consideration for the application of chloroquine is its QTc-prolonging potential. Thus far, no data are available on the QTc-prolonging potential of chloroquine in COVID-19 patients. OBJECTIVE: To assess the degree of chloroquine-induced QTc prolongation in hospitalised COVID-19 patients. METHODS: A baseline electrocardiogram (ECG) and ECGs recorded during chloroquine treatment were retrospectively collected in patients suspected of having COVID-19. The QTc interval was calculated by computerised and manual interpretation. Baseline and follow-up QTc intervals were compared using the paired samples t-test. RESULTS: A total of 95 patients had a baseline ECG recording and at least one ECG recording during chloroquine therapy. Chloroquine treatment resulted in a mean QTc prolongation of 35 ms (95% CI 28-43 ms) using computerised interpretation and 34 ms (95% CI 25-43 ms) using manual interpretation. No torsade de pointes was observed during chloroquine treatment. After manual review, 22 patients (23%) had a QTc interval exceeding 500 ms during chloroquine treatment. None of these patients had a prolonged QTc interval prior to the initiation of chloroquine treatment. CONCLUSIONS: Chloroquine significantly prolongs the QTc interval in a clinically relevant matter. This highlights the need for ECG monitoring when prescribing chloroquine to COVID-19 patients.
BACKGROUND: In the battle against the SARS-CoV‑2 pandemic, chloroquine has emerged as a new potential therapeutic option for the treatment of infectedpatients. A safety consideration for the application of chloroquine is its QTc-prolonging potential. Thus far, no data are available on the QTc-prolonging potential of chloroquine in COVID-19patients. OBJECTIVE: To assess the degree of chloroquine-induced QTc prolongation in hospitalised COVID-19patients. METHODS: A baseline electrocardiogram (ECG) and ECGs recorded during chloroquine treatment were retrospectively collected in patients suspected of having COVID-19. The QTc interval was calculated by computerised and manual interpretation. Baseline and follow-up QTc intervals were compared using the paired samples t-test. RESULTS: A total of 95 patients had a baseline ECG recording and at least one ECG recording during chloroquine therapy. Chloroquine treatment resulted in a mean QTc prolongation of 35 ms (95% CI 28-43 ms) using computerised interpretation and 34 ms (95% CI 25-43 ms) using manual interpretation. No torsade de pointes was observed during chloroquine treatment. After manual review, 22 patients (23%) had a QTc interval exceeding 500 ms during chloroquine treatment. None of these patients had a prolonged QTc interval prior to the initiation of chloroquine treatment. CONCLUSIONS:Chloroquine significantly prolongs the QTc interval in a clinically relevant matter. This highlights the need for ECG monitoring when prescribing chloroquine to COVID-19patients.
Authors: Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba Journal: J Am Coll Cardiol Date: 2010-03-02 Impact factor: 24.094
Authors: Fawaz Mzayek; Haiyan Deng; Frances J Mather; Elizabeth C Wasilevich; Huayin Liu; Christiane M Hadi; David H Chansolme; Holly A Murphy; Bekir H Melek; Alan N Tenaglia; David M Mushatt; Albert W Dreisbach; Juan J L Lertora; Donald J Krogstad Journal: PLoS Clin Trials Date: 2007-01-05
Authors: Sasithon Pukrittayakamee; Joel Tarning; Podjanee Jittamala; Prakaykaew Charunwatthana; Saranath Lawpoolsri; Sue J Lee; Warunee Hanpithakpong; Borimas Hanboonkunupakarn; Nicholas P J Day; Elizabeth A Ashley; Nicholas J White Journal: Antimicrob Agents Chemother Date: 2014-03-31 Impact factor: 5.191
Authors: James A Watson; Joel Tarning; Richard M Hoglund; Frederic J Baud; Bruno Megarbane; Jean-Luc Clemessy; Nicholas J White Journal: Elife Date: 2020-07-08 Impact factor: 8.140
Authors: Angelos Arfaras-Melainis; Andreas Tzoumas; Damianos G Kokkinidis; Maria Salgado Guerrero; Dimitrios Varrias; Xiaobo Xu; Luis Cerna; Ricardo Avendano; Cameron Kemal; Leonidas Palaiodimos; Robert T Faillace Journal: J Cardiovasc Dev Dis Date: 2021-05-13